JP2023088944A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023088944A5 JP2023088944A5 JP2023040600A JP2023040600A JP2023088944A5 JP 2023088944 A5 JP2023088944 A5 JP 2023088944A5 JP 2023040600 A JP2023040600 A JP 2023040600A JP 2023040600 A JP2023040600 A JP 2023040600A JP 2023088944 A5 JP2023088944 A5 JP 2023088944A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- csa
- dose
- plasma concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 35
- 230000036470 plasma concentration Effects 0.000 claims 15
- 206010019280 Heart failures Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000012190 activator Substances 0.000 claims 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 210000004165 myocardium Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 102400001263 NT-proBNP Human genes 0.000 claims 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025121073A JP2025165979A (ja) | 2017-06-30 | 2025-07-18 | 心筋節活性化剤で心不全を治療する方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527983P | 2017-06-30 | 2017-06-30 | |
| US62/527,983 | 2017-06-30 | ||
| PCT/US2018/040181 WO2019006235A1 (en) | 2017-06-30 | 2018-06-29 | METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS |
| JP2019570045A JP2020526483A (ja) | 2017-06-30 | 2018-06-29 | 心筋節活性化剤で心不全を治療する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570045A Division JP2020526483A (ja) | 2017-06-30 | 2018-06-29 | 心筋節活性化剤で心不全を治療する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025121073A Division JP2025165979A (ja) | 2017-06-30 | 2025-07-18 | 心筋節活性化剤で心不全を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023088944A JP2023088944A (ja) | 2023-06-27 |
| JP2023088944A5 true JP2023088944A5 (enExample) | 2023-09-01 |
Family
ID=63013097
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570045A Pending JP2020526483A (ja) | 2017-06-30 | 2018-06-29 | 心筋節活性化剤で心不全を治療する方法 |
| JP2023040600A Pending JP2023088944A (ja) | 2017-06-30 | 2023-03-15 | 心筋節活性化剤で心不全を治療する方法 |
| JP2025121073A Pending JP2025165979A (ja) | 2017-06-30 | 2025-07-18 | 心筋節活性化剤で心不全を治療する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570045A Pending JP2020526483A (ja) | 2017-06-30 | 2018-06-29 | 心筋節活性化剤で心不全を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025121073A Pending JP2025165979A (ja) | 2017-06-30 | 2025-07-18 | 心筋節活性化剤で心不全を治療する方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11576910B2 (enExample) |
| EP (2) | EP4512470A3 (enExample) |
| JP (3) | JP2020526483A (enExample) |
| CN (1) | CN110996953A (enExample) |
| AU (2) | AU2018290983B2 (enExample) |
| BR (1) | BR112019028046A2 (enExample) |
| CA (1) | CA3068588A1 (enExample) |
| DK (1) | DK3645002T3 (enExample) |
| ES (1) | ES3008457T3 (enExample) |
| FI (1) | FI3645002T3 (enExample) |
| HR (1) | HRP20241729T1 (enExample) |
| HU (1) | HUE069805T2 (enExample) |
| LT (1) | LT3645002T (enExample) |
| MA (1) | MA49508B1 (enExample) |
| MD (1) | MD3645002T2 (enExample) |
| MX (2) | MX2020000190A (enExample) |
| PL (1) | PL3645002T3 (enExample) |
| PT (1) | PT3645002T (enExample) |
| RS (1) | RS66581B1 (enExample) |
| SI (1) | SI3645002T1 (enExample) |
| SM (1) | SMT202500067T1 (enExample) |
| WO (1) | WO2019006235A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014240049C1 (en) | 2013-03-14 | 2019-03-07 | Amgen Inc. | Heterocyclic compounds and their uses |
| US11040956B2 (en) | 2017-06-30 | 2021-06-22 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| LT3645002T (lt) | 2017-06-30 | 2025-02-10 | Amgen Inc. | Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais |
| HUE052049T2 (hu) | 2018-07-09 | 2021-04-28 | Fis Fabbrica Italiana Sintetici Spa | Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására |
| JP2021534138A (ja) | 2018-08-17 | 2021-12-09 | アムジエン・インコーポレーテツド | オメカムチブメカルビルの塩及び結晶形態 |
| CA3138080A1 (en) * | 2019-05-19 | 2020-11-26 | Jean-Francois TAMBY | Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl) n-(isoxazol-3-yl)piperidine-1-carboxamid |
| CA3168513A1 (en) * | 2020-02-10 | 2021-08-19 | Amgen Inc. | Omecamtiv mecarbil tablet |
| IL298885A (en) * | 2020-06-15 | 2023-02-01 | Myokardia Inc | Treatment of atrial function |
| TW202233189A (zh) * | 2020-11-12 | 2022-09-01 | 美商安進公司 | 藉由投與奧美卡替莫卡必爾治療心臟衰竭之方法 |
| CN116710139A (zh) * | 2020-11-12 | 2023-09-05 | 安进股份有限公司 | 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法 |
| TW202300479A (zh) | 2021-03-10 | 2023-01-01 | 美商安進公司 | 奧美卡替莫卡必爾之合成 |
| WO2023164452A2 (en) * | 2022-02-22 | 2023-08-31 | Yale University | Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth |
| IL319671A (en) | 2022-09-26 | 2025-05-01 | Edgewise Therapeutics Inc | 4,1-Dihydroquinazolinone compounds and their uses |
| WO2024081611A1 (en) * | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| JP7858148B1 (ja) | 2023-03-27 | 2026-05-13 | エッジワイズ セラピューティクス， インコーポレイテッド | キナゾリンジオン化合物およびその使用 |
| EP4688748A1 (en) | 2023-03-27 | 2026-02-11 | Edgewise Therapeutics, Inc. | Quinolinone amide compounds and uses thereof |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| WO2026050494A1 (en) | 2024-08-29 | 2026-03-05 | Cytokinetics, Incorporated | Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| AU2546399A (en) | 1998-02-10 | 1999-08-30 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparations with controlled release |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| EP1551505B1 (en) | 2002-10-04 | 2010-02-24 | Microchips, Inc. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
| BRPI0512193B8 (pt) | 2004-06-17 | 2021-05-25 | Cytokinetics Inc | composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal |
| ES2419007T3 (es) | 2005-12-15 | 2013-08-19 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y procedimientos |
| WO2007133747A2 (en) | 2006-05-15 | 2007-11-22 | Wisconsin Alumni Research Foundation | PULMONARY DELIVERY OF 1α,25-DIHYDROXYVITAMIN D3 AND CO-ADMINISTRATION OF PARATHYROID HORMONE OR CALCITONIN |
| FR2902092B1 (fr) | 2006-06-07 | 2008-09-05 | Sapelem Soc Par Actions Simpli | Appareil de manutention de charge |
| EP2139458A4 (en) | 2007-04-19 | 2013-01-23 | Dong A Pharm Co Ltd | BIODEGRADABLE MICRO BEADS COMPOSITION FOR CONTROLLED RELEASE OF GLUCOSE-CONTROLLED PEPTIDE AND FORMULATION THEREOF |
| AU2014240049C1 (en) | 2013-03-14 | 2019-03-07 | Amgen Inc. | Heterocyclic compounds and their uses |
| AU2014240104B2 (en) * | 2013-03-14 | 2018-11-08 | Amgen Inc. | Heterocyclic compounds and their uses |
| CA2975260C (en) | 2015-01-29 | 2024-05-21 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| US10543215B2 (en) | 2015-06-26 | 2020-01-28 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
| US20200087367A1 (en) | 2017-02-06 | 2020-03-19 | Acceleron Pharma Inc. | Compositions and methods for treating heart failure |
| LT3645002T (lt) | 2017-06-30 | 2025-02-10 | Amgen Inc. | Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais |
| US11040956B2 (en) | 2017-06-30 | 2021-06-22 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| HUE052049T2 (hu) | 2018-07-09 | 2021-04-28 | Fis Fabbrica Italiana Sintetici Spa | Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására |
| US11608318B2 (en) | 2018-07-12 | 2023-03-21 | Assia Chemical Industries Ltd. | Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl |
| EP3599243B1 (en) | 2018-07-26 | 2023-04-12 | CVIE Therapeutics Limited | 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure |
| JP2021534138A (ja) | 2018-08-17 | 2021-12-09 | アムジエン・インコーポレーテツド | オメカムチブメカルビルの塩及び結晶形態 |
| WO2020131574A1 (en) | 2018-12-18 | 2020-06-25 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| EP3934654B1 (en) | 2019-03-05 | 2026-04-29 | Windtree Therapeutics, Inc. | Istaroxime or its metabolite pst-3093 for use as intravenous formulation for the treatment of acute heart failure (ahf) |
| WO2021053189A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| EP4041710A1 (en) | 2019-10-09 | 2022-08-17 | Dr. Reddy's Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
| US20220402874A1 (en) | 2019-10-09 | 2022-12-22 | Dr. Reddy's Laboratories Limited | Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof |
| CN114945372A (zh) | 2019-11-10 | 2022-08-26 | 迈奥卡迪亚公司 | 用肌球蛋白调节剂的治疗方法 |
| GB201918853D0 (en) | 2019-12-19 | 2020-02-05 | Lund Lars H | Methods of treatment |
| CN114929671B (zh) | 2020-01-03 | 2024-04-16 | 苏州科睿思制药有限公司 | 化合物i二盐酸盐的共晶及其制备方法和用途 |
| CA3168513A1 (en) | 2020-02-10 | 2021-08-19 | Amgen Inc. | Omecamtiv mecarbil tablet |
| TW202233189A (zh) | 2020-11-12 | 2022-09-01 | 美商安進公司 | 藉由投與奧美卡替莫卡必爾治療心臟衰竭之方法 |
| TW202300479A (zh) | 2021-03-10 | 2023-01-01 | 美商安進公司 | 奧美卡替莫卡必爾之合成 |
| WO2023205291A2 (en) | 2022-04-21 | 2023-10-26 | The Board Of Regents Of The University Of Oklahoma | Targeting myocardial tissue for delivery of therapeutic and imaging agents |
| WO2024081611A1 (en) | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| US11986474B1 (en) * | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
-
2018
- 2018-06-29 LT LTEPPCT/US2018/040181T patent/LT3645002T/lt unknown
- 2018-06-29 AU AU2018290983A patent/AU2018290983B2/en active Active
- 2018-06-29 EP EP24209435.7A patent/EP4512470A3/en active Pending
- 2018-06-29 RS RS20250023A patent/RS66581B1/sr unknown
- 2018-06-29 JP JP2019570045A patent/JP2020526483A/ja active Pending
- 2018-06-29 SI SI201831198T patent/SI3645002T1/sl unknown
- 2018-06-29 US US16/625,958 patent/US11576910B2/en active Active
- 2018-06-29 ES ES18745732T patent/ES3008457T3/es active Active
- 2018-06-29 DK DK18745732.0T patent/DK3645002T3/da active
- 2018-06-29 HR HRP20241729TT patent/HRP20241729T1/hr unknown
- 2018-06-29 WO PCT/US2018/040181 patent/WO2019006235A1/en not_active Ceased
- 2018-06-29 MD MDE20200488T patent/MD3645002T2/ro unknown
- 2018-06-29 PT PT187457320T patent/PT3645002T/pt unknown
- 2018-06-29 EP EP18745732.0A patent/EP3645002B1/en active Active
- 2018-06-29 BR BR112019028046-4A patent/BR112019028046A2/pt not_active Application Discontinuation
- 2018-06-29 SM SM20250067T patent/SMT202500067T1/it unknown
- 2018-06-29 MA MA49508A patent/MA49508B1/fr unknown
- 2018-06-29 CA CA3068588A patent/CA3068588A1/en active Pending
- 2018-06-29 HU HUE18745732A patent/HUE069805T2/hu unknown
- 2018-06-29 MX MX2020000190A patent/MX2020000190A/es unknown
- 2018-06-29 PL PL18745732.0T patent/PL3645002T3/pl unknown
- 2018-06-29 CN CN201880053343.0A patent/CN110996953A/zh active Pending
- 2018-06-29 FI FIEP18745732.0T patent/FI3645002T3/fi active
-
2020
- 2020-01-08 MX MX2022015115A patent/MX2022015115A/es unknown
-
2023
- 2023-01-17 US US18/155,483 patent/US12295952B2/en active Active
- 2023-03-15 JP JP2023040600A patent/JP2023088944A/ja active Pending
- 2023-05-05 US US18/313,267 patent/US11931358B2/en active Active
-
2024
- 2024-02-15 AU AU2024200991A patent/AU2024200991B2/en active Active
-
2025
- 2025-04-18 US US19/183,619 patent/US20250255862A1/en active Pending
- 2025-07-18 JP JP2025121073A patent/JP2025165979A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3645002T3 (fi) | Menetelmiä sydämen vajaatoiminnan hoitamiseksi sydämen sarkomeerin aktivaattoreilla | |
| KR101653071B1 (ko) | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 | |
| US3795739A (en) | Treatment of parkinson disease | |
| JP2020526483A5 (enExample) | ||
| FI4243825T3 (fi) | Omekamtiivimekarbiili sydämen vajaatoiminnan hoitoon valikoiduilla potilasryhmillä | |
| JP2020529996A5 (enExample) | ||
| JP2022537551A5 (enExample) | ||
| JP2015057436A5 (enExample) | ||
| CN1856339A (zh) | 肺动脉高血压症治疗的伊洛前列素联合疗法 | |
| WO2007149283B1 (en) | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload | |
| Mooss et al. | Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia | |
| JP2024533756A5 (enExample) | ||
| JP2024178420A5 (enExample) | ||
| JP2020529440A5 (enExample) | ||
| EP2988750B1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| JP2022518944A5 (enExample) | ||
| JP2024019691A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| JP2024531188A5 (enExample) | ||
| CN104039148A (zh) | 组合als疗法 | |
| JP3084059B2 (ja) | 甲状腺ホルモン心臓治療 | |
| JP2022514537A5 (enExample) | ||
| JP2011518147A (ja) | 血中カリウム濃度を調節する薬剤を調製するためのドロネダロンまたは医薬的に許容されるこの塩の使用 | |
| JP2012525358A5 (enExample) | ||
| JP2025509278A5 (enExample) | ||
| JP2011522875A (ja) | 電気的除細動を予防するためのドロネダロン |